Beam Therapeutics Inc. (BEAM) Institutional Ownership

Ownership Summary

Beam Therapeutics Inc. (NASDAQ:BEAM) showed up in the 13F filings of 237 institutional investors as of December 2025.

• These investors held 101.5% of outstanding shares in December 2025, down from 115.1% in September 2025.
• They decreased total shares held in Beam Therapeutics by -5.98% from the prior quarter, while the number of investors in BEAM increased 3.95% year over year.
• Of these 237 funds, 135 grew their exposure to Beam Therapeutics, 63 cut back, and 39 maintained positions.
• Institutional investors collectively held 104.07Mn shares in Beam Therapeutics as of December 2025, down by 6.62Mn shares quarter on quarter, and up 21.44Mn shares year over year.
• FMR LLC leads ownership in BEAM with 12.45Mn shares as of December 31, 2025, equal to 12.14% of outstanding shares.
• The biggest buyers of Beam Therapeutics for the quarter ending December 2025 included VANGUARD PORTFOLIO MANAGEMENT LLC (4.57Mn), VANGUARD CAPITAL MANAGEMENT LLC (4.38Mn), PRICE T ROWE ASSOCIATES INC /MD/ (2.71Mn), ADAR1 Capital Management, LLC (1.45Mn), Kynam Capital Management, LP (1.24Mn).
• The largest sellers of Beam Therapeutics for the quarter ending December 2025 were MARSHALL WACE, LLP (806.59K), Amova Asset Management Americas, Inc. (583.72K), Sumitomo Mitsui Trust Group, Inc. (583.72K), ARK Investment Management LLC (333.76K), MILLENNIUM MANAGEMENT LLC (279.42K).
• Per Business Quant, the top 10 investors in BEAM for the quarter ending December 2025 include FMR LLC (12.45Mn), ARK Investment Management LLC (12.13Mn), FARALLON CAPITAL MANAGEMENT, L.L.C. (10.13Mn), BlackRock, Inc. (8.49Mn), State Street Corp (5.7Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (4.57Mn), ARCH Venture Management, LLC (4.54Mn), VANGUARD CAPITAL MANAGEMENT LLC (4.38Mn), Amova Asset Management Americas, Inc. (3.83Mn), Sumitomo Mitsui Trust Group, Inc. (3.83Mn).